Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe ... (ied a panel of microRNA biomarkers poten...)

HOME >> BIOLOGY >> TECHNOLOGY

Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe Technology

Date:12/11/2007

ied a panel of microRNA biomarkers potentially allowing for differentiation between these cancer types.

Cancer of Unknown Primary (CUP) - This test is designed to assist clinicians to accurately identify the origin of metastases. In 3%-5% of all cancer patients, clinicians cannot identify the origin of a patients' tumor. This information is crucial for determining treatment type. Rosetta Genomics has developed a panel of microRNA biomarkers potentially able to identify approximately thirty cancers

"Our proprietary microRNA detection and quantitation technologies are at the heart of our sensitive diagnostic products," noted Amir Avniel, President and CEO of Rosetta Genomics." Using very small amounts of tissue samples or body fluids, we are able to detect microRNAs on the order of single molecules, as well as differentiate microRNAs with only a single nucleotide mismatch. We look forward to the launch of our first diagnostic products in 2008."

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs.

The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rose
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
9. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics

Post Your Comments:

Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogen's MGB Probe ...(ied a panel of microRNA biomarkers poten...)